# The Honorable Gary Peters 

724 Hart Senate Office Building Washington, DC 20510

The Honorable Sherrod Brown
503 Hart Senate Office Building
Washington, DC 20510-3505
The Honorable Marsha Blackburn
357 Dirksen Senate Office Building
Washington, DC 20510

Dear Senators Peters, Brown, and Blackburn:
We write to express our strong support for the RAPID Reserve Act (S. 2510). As members of the Securing America's Medicines and Supply Coalition (SAMS), we represent a group of leading, global life sciences and technology companies with the goal of advancing policy that fosters U.S.-made manufacturing of important pharmaceutical products, devices, and personal protective equipment (PPE).

SAMS supports policies that:

- Encourage increased manufacturing operations within U.S. borders for the U.S. medical supply chain via reforms to trade and tax law through policies that promote domestic production.
- Maintain and expand U.S. government loan, grant, direct investment, and purchase agreement programs for U.S.-manufactured essential medical products and infrastructure.
- Broaden opportunities within the Department of Health and Human Services (including the Centers for Medicare and Medicaid), the Veterans Administration, and the Department of Defense to promote and procure U.S.-made pharmaceutical products and supplies.
- Strengthen the Strategic National Stockpile (SNS) for essential pharmaceuticals, diagnostics, medical devices, and PPE, with an emphasis on those produced domestically.

The RAPID Reserve Act strongly aligns with SAMS's ongoing goals. Specifically, we support measures in the bill that would help onshore the production of active pharmaceutical ingredients (API) and drug products, which is a critical step in mitigating ongoing drug shortages.

Thank you for your leadership on this important issue and we look forward to working with your offices to advance this important piece of legislation.

Sincerely,
Securing America's Medicines and Supply
fluidIQ

US BIOLOGIC

